| 多西紫杉醇单药化疗在老年中晚期非小细胞肺癌的近期疗效分析 |
| |
| 引用本文： | 胡晓璐,杨毅,李高峰. 多西紫杉醇单药化疗在老年中晚期非小细胞肺癌的近期疗效分析[J]. 现代保健, 2011, 0(6): 32-33 |
| |
| 作者姓名： | 胡晓璐 杨毅 李高峰 |
| |
| 作者单位： | 昆明医学院第三附属医院云南省肿瘤医院,650118 |
| |
| 基金项目： | 云南省科技厅社会发展科技计划应用基础研究项目（项目批准号：2009ZC120M）;云南省教育厅资助项目（项目批准号：09y0173） |
| |
| 摘 要： | 目的 观察了解多西紫杉醇单药化疗在老年晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应.方法 29例Ⅲ～Ⅳ期NSCLC老年患者均经病理组织学和（或）细胞学检查确诊.多西紫杉醇单药治疗后评价疗效.结果 29例患者均可评价,获得CR 2例,PR 10例,有效率41.4%（12/29）.1年生存率为48.3%（14/29）.最主要的毒副反应为白细胞及血小板降低,但均可耐受.结论 多西紫杉醇单药化疗治疗老年晚期NSCLC有较好疗效,可明显改善患者生存质量,毒副反应轻,易于耐受.
|
| 关 键 词： | 非小细胞肺癌 多西紫杉醇 老年患者 |
Clinical observation of docetaxel in treating elder advanced non-small cell lung cancer |
| |
| HU Xiao-lu,YANG Yi,LI Gao-feng. Clinical observation of docetaxel in treating elder advanced non-small cell lung cancer[J]. , 2011, 0(6): 32-33 |
| |
| Authors: | HU Xiao-lu YANG Yi LI Gao-feng |
| |
| Affiliation: | (The 3rd Affiliated Hospital of Kunming Medical College, Kunming 650118, China) |
| |
| Abstract: | Objective To evaluate the clinical effect and toxieity of docetaxel in treating elder advanced non - small cell lung cancer（NSCLC）. Methods 29 patients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study. The patients received and were evaluated effect after 2 - 4 cycles. Results Complete remisson （CR） was observrd in 2 cases and PR in 10 cases, the total response rate was 41.4% （12/29）. 1 - year survival rate was 48. 3% （14/29）. The main side effects were leucopenia and thrombocytopenia, but they were tolerable. Conclusion The regimen of pemetrexed plus cisplation is effective, safe and well - tolerable in the treatment of eider advanced NSCLC. It significantly prolong the patients, survival time. |
| |
| Keywords: | Non - small cell lung cancer（NSCLC） Pemetrexed Chemotherapy Elder patients |
| 本文献已被 维普 等数据库收录！ |
